Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback